Lung Squamous Cell Carcinoma

In a phase II trial, patients with squamous non-small cell lung cancer who had progressed at least one prior platinum-based chemotherapy with CCND1/2/3 or CDK 4 amplification were treated with palboci… (full text at CIViC)

PMID 31302234 · Edelman et al., 2019 · Open in CIViC

In a phase II trial, patients with squamous non-small cell lung cancer who had progressed at least one prior platinum-based chemotherapy with CCND1/2/3 or CDK 4 amplification were treated with palboci… (full text at CIViC)

PMID 31302234 · Edelman et al., 2019 · Open in CIViC

In a phase II trial, patients with squamous non-small cell lung cancer who had progressed at least one prior platinum-based chemotherapy with CCND1/2/3 or CDK 4 amplification were treated with palboci… (full text at CIViC)

PMID 31302234 · Edelman et al., 2019 · Open in CIViC

In this study, PD-L1 expression (measured by IHC) was associated with better overall survival in the subgroup of Lung Squamous Cell Carcinomas (149 of 321 patients in the study).

PMID 26313362 · Schmidt et al., 2015 · Open in CIViC

The NCI-H2286 lung squamous cell carcinoma cell line, containing the DDR2 I638F mutation was shown to be sensitive (IC50 139nm) to dasatinib in-vitro. Dasatanib sensitivity was demonstrated in-vivo us… (full text at CIViC)

PMID 22328973 · Hammerman et al., 2011 · Open in CIViC

In a patient expressing a DDR2 S768R mutation, treatment with dasatinib plus erlotinib acheived a partial response.

PMID 22328973 · Hammerman et al., 2011 · Open in CIViC

A patient with stage IV lung squamous cell carcinoma harboring an EGFR G719C mutation and high PD-L1 expression (tumor proportion score of 90%) experienced disease progression after 1.5 months of afat… (full text at CIViC)

PMID 40959071 · Fu et al., 2025 · Open in CIViC

A 57-year old male with no significant smoking history presented with lung squamous cell carcinoma in the right lung. Oncomine Dx Target Test was done and revealed EGFR exon 19 deletion and de novo EG… (full text at CIViC)

PMID 37641467 · Maeda et al., 2023 · Open in CIViC

In this study in surgically resected squamous cell lung cancer, FGFR1 amplification has been shown as an independent negative prognostic factor in Asian patients. FGFR1 amplification also correlates w… (full text at CIViC)

PMID 23182986 · Kim et al., 2013 · Open in CIViC

Effect of FGFR1 amplification on survival unclear, no significant correlation with PFS and OS seen in this meta-analysis. However, FGFR1 amplification is significantly correlated with lymph node metas… (full text at CIViC)

PMID 25433983 · Jiang et al., 2015 · Open in CIViC

This study shows an association of FGFR1 amplification with shorter overall and disease-free survival. However, no statistically significant association is seen on multivariate analysis.

Patient diagnosed with metastatic squamous cell lung cancer had high-level amplification of FGFR1 and high expression of MYC. Patient was treated with 400 mg pazopanib twice a day. CT taken four and… (full text at CIViC)

PMID 24302556 · Malchers et al., 2014 · Open in CIViC

NIH-3T3 cells with the FGFR2 K660E kinase domain mutation demonstrated an increase in colony formation relative to wild-type in an anchorage-independence assay, which was lost with the introduction of… (full text at CIViC)

PMID 23786770 · Liao et al., 2013 · Open in CIViC

NIH-3T3 cells with the FGFR2 S320C extracellular domain mutation demonstrated an increase in colony formation in an anchorage-independence assay, which was lost with the introduction of AP24534, BGJ39… (full text at CIViC)

PMID 23786770 · Liao et al., 2013 · Open in CIViC

NIH-3T3 cells with the FGFR2 W290C extracellular domain mutation demonstrated an increase in colony formation in an anchorage independent growth assay, which was lost with the introduction of AP24534,… (full text at CIViC)

PMID 23786770 · Liao et al., 2013 · Open in CIViC

NIH-3T3 cells with the FGFR3 R248C extracellular domain mutation demonstrated an increase in colony formation compared to wild-type in an anchorage-independence assay, which was counteracted by treatm… (full text at CIViC)

PMID 23786770 · Liao et al., 2013 · Open in CIViC

NIH-3T3 cells with the FGFR3 S249C extracellular domain mutation demonstrated an increase in colony formation compared to wild-type in an anchorage-independence assay, which was counteracted by the tr… (full text at CIViC)

PMID 23786770 · Liao et al., 2013 · Open in CIViC

In preclinical lung squamous cell carcinoma models, KMT2D loss increased sensitivity to SHP2 inhibition (SHP099) and pan-ERBB inhibition (afatinib). Enhanced growth suppression was observed in Kmt2d-d… (full text at CIViC)

PMID 36525973 · Pan et al., 2023 · Open in CIViC

In an in vitro study, the A549 cell line, which harbors the KRAS G12S mutation, was found to have insensitivity to dasatinib treatment (IC50: 7.4 uM). In in vivo experiments, KRAS G12S expressing A549… (full text at CIViC)

PMID 22328973 · Hammerman et al., 2011 · Open in CIViC

A retrospective study of tumors sequenced through the Veterans Health Administration National Precision Oncology Program identified NTRK rearrangements in 25 of 22,450 solid tumors. Twelve patients wi… (full text at CIViC)

PMID 36926986 · Zhou et al., 2023 · Open in CIViC

Case report of a 73 year old patient with advanced squamous cell carcinoma of the lung that tested negative for EGFR, KRAS and PIK3CA mutations and ALK and ROS1 rearrangements. c-MET amplification was… (full text at CIViC)

PMID 24192513 · Schwab et al., 2014 · Open in CIViC

In a metastatic lung squamous cell carcinoma patient harboring a MET D1010N mutation, MET D1010N mutation was associated with response to crizotinib monotherapy. The patient maintained initial respons… (full text at CIViC)

PMID 27022036 · Heist et al., 2016 · Open in CIViC

In a cohort of 178 patients with lung squamous cell carcinoma from The Cancer Genome Atlas, high neoantigen burden was significantly associated with improved disease-free survival compared with low ne… (full text at CIViC)

PMID 30824826 · Chae et al., 2019 · Open in CIViC

In a phase 2 trial, patients with squamous cell lung carcinoma harboring NFE2L2 mutation were treated with oral TORC1/2 inhibitor TAK228. ORR 25% (1 PR, 3 SD, 0 PD).

Open in CIViC

In an NCI-CTEP phase 2 trial, patients with squamous cell lung carcinoma with NFE2L2 mutations were treated with TORC1/2 inhibitor TAK-228. The response rate was 29% (2/7）and disease control rate was … (full text at CIViC)

Open in CIViC

Cell line NCI-H1703 is PDGFRA amplified and KIT wild-type. NCI-H1703 was treated with a PDGFRA inhibitor, imatinib or sunitinib. The IC50 of imatinib or sunitinib was lower in PDGFRA amplified NCI-H… (full text at CIViC)

PMID 19755855 · Ramos et al., 2009 · Open in CIViC

This is part of the randomised double-blind phase 3 trial, CameL-sq, a study that assessed the therapeutic effectiveness of the PD-1 blockade, camrelizumab plus chemotherapy as first-line treatment in… (full text at CIViC)

PMID 34980131 · Jiang et al., 2022 · Open in CIViC